Intervention

Ruxolitinib

ClinicalTrials.gov intervention label

Clinical trials19
Recruiting3
Common conditions25
Lead sponsors shown13

Clinical trials

19 shown
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT06616155 · 2026-06-01
RECRUITING
Retifanlimab and Ruxolitinib In Solid MalignanciesNCT07219576 · 2026-01-08
RECRUITING
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 · 2022-06-09
RECRUITING
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16
ACTIVE_NOT_RECRUITING
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeNCT05413356 · 2022-06-01
UNKNOWN
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Ruxolitinib for Premalignant Breast DiseaseNCT02928978 · 2018-05-13
COMPLETED
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerNCT02876302 · 2018-01-24
COMPLETED
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940 · 2016-11-30
ACTIVE_NOT_RECRUITING
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesNCT02711137 · 2016-05-18
TERMINATED
Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsNCT02475655 · 2016-05-16
COMPLETED
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibNCT02155465 · 2014-06-01
COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerNCT02066532 · 2014-06-01
COMPLETED
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerNCT02120417 · 2014-05-01
TERMINATED
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNCT02119650 · 2014-02-11
TERMINATED
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaNCT02041429 · 2014-02-01
COMPLETED
Ruxolitinib in Patients With Breast CancerNCT01562873 · 2012-06-01
TERMINATED
Ruxolitinib in Estrogen Receptor Positive Breast CancerNCT01594216 · 2012-04-01
COMPLETED
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerNCT00638378 · 2008-02-01
TERMINATED

Common conditions

Breast Cancer3Anatomic Stage IV Breast Cancer AJCC v82Castration-Resistant Prostate Carcinoma2Lung Cancer2Metastatic Breast Cancer2Metastatic Malignant Solid Neoplasm2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Atypical Ductal Hyperplasia1Atypical Lobular Hyperplasia1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Breast Carcinoma1Bronchiolitis Obliterans Syndrome1Carcinoma, Non-Small-Cell Lung1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Clinical Stage IV Cutaneous Melanoma AJCC v81Colorectal Cancer (CRC)1Ductal Carcinoma In Situ1Estrogen-receptor Positive Invasive Metastatic Breast Cancer1Hematologic Malignancy1

Trial status mix

COMPLETED7
TERMINATED6
RECRUITING3
ACTIVE_NOT_RECRUITING2
UNKNOWN1

Phase mix

PHASE217
PHASE18

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.